文献速递头痛与眩晕

阿托吉泮预防性治疗偏头痛对患者报告结局的影响:随机双盲3期ADVANCE试验

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.
PubMed 文献 · Neurology · 2022-11-17

ADVANCE试验在每月4-14个偏头痛日的成人中评估阿托吉泮(10、30、60 mg每日一次)与安慰剂相比对患者报告结局的影响。12周时,所有阿托吉泮组MSQ角色功能-限制域改善均显著优于安慰剂,30 mg和60 mg组AIM-D日常活动表现和躯体损伤域也显著改善,10 mg组未达显著。

要点

  • 阿托吉泮10、30、60 mg组12周MSQ-RFR改善均显著优于安慰剂。
  • 阿托吉泮30 mg和60 mg组AIM-D日常活动表现和躯体损伤域显著改善。
  • 阿托吉泮10 mg组AIM-D日常活动表现和躯体损伤域改善未达统计学显著。

核心结论

  • 阿托吉泮30 mg和60 mg在MSQ-RFR及AIM-D两个域等关键患者报告结局上产生显著改善。
  • 其他MSQ域和HIT-6也出现名义上的改善,支持阿托吉泮作为偏头痛预防新疗法的获益。
  • 该研究提供II级证据表明每日阿托吉泮与每月4-14个偏头痛日患者的健康相关生活质量指标改善相关。

研究设计与样本

  • 3期、12周、多中心、随机、双盲、安慰剂对照、平行组ADVANCE试验。
  • 每月4-14个偏头痛日的成人接受阿托吉泮10、30或60 mg每日一次或安慰剂。
  • 910例参与者被随机分组,改良意向治疗人群873例(阿托吉泮10 mg n=214;30 mg n=223;60 mg n=222;安慰剂 n=214)。
  • 试验注册:ClinicalTrials.gov NCT03777059,提交于2018年12月13日,首例患者入组于2018年12月14日。

主要发现

  • 12周时MSQ角色功能-限制域相对安慰剂的LSMD:10 mg为9.9,30 mg为10.1,60 mg为10.8,均p<0.0001,超过最小临床重要组间差异3.2分。
  • 12周治疗期间每月AIM-D日常活动表现域LSMD:30 mg为-2.54(p=0.0003),60 mg为-3.32(p<0.0001);10 mg为-1.19(p=0.086)。
  • 12周治疗期间每月AIM-D躯体损伤域LSMD:30 mg为-1.99(p=0.0011),60 mg为-2.46(p<0.0001);10 mg为-1.08(p=0.074)。
  • 探索性分析中,阿托吉泮30 mg和60 mg与MSQ角色功能-预防域和情绪功能域、其他AIM-D结局及HIT-6评分在最早时间点(第4周)及整个12周治疗期间出现名义上的改善相关。
  • 阿托吉泮10 mg的结果不一。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The oral calcitonin gene-related peptide receptor antagonist atogepant is indicated for the preventive treatment of episodic migraine. We evaluated changes in patient-reported outcomes with atogepant in adults with migraine. METHODS: In this phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial (ADVANCE), adults with 4-14 migraine days per month received atogepant (10, 30, or 60 mg) once daily or placebo. Secondary endpoints included changes from baseline in Migraine-Specific Quality-of-Life Questionnaire (MSQ) version 2.1 Role Function-Restrictive (RFR) domain at week 12 and mean monthly Activity Impairment in Migraine-Diary (AIM-D) Performance of Daily Activities (PDA) and Physical Impairment (PI) domains across the 12-week treatment period. Exploratory endpoints included change in MSQ Role Function-Preventive (RFP) and Emotional Function (EF) domains; AIM-D total scores; and change in Headache Impact Test (HIT)-6 scores. RESULTS: Of 910 participants randomized, 873 comprised the modified intent-to-treat population (atogepant: 10 mg [n = 214]; 30 mg [n = 223]; and 60 mg [n = 222]; placebo [n = 214]). All atogepant groups demonstrated significantly greater improvements vs placebo in MSQ RFR that exceeded minimum clinically meaningful between-group difference (3.2 points) at week 12 (least-square mean difference [LSMD] vs placebo: 10 mg [9.9]; 30 mg [10.1]; 60 mg [10.8]; all p < 0.0001). LSMDs in monthly AIM-D PDA and PI scores across the 12-week treatment period improved significantly for the atogepant 30 (PDA: -2.54; p = 0.0003; PI: -1.99; and p = 0.0011) and 60 mg groups (PDA: -3.32; p < 0.0001; PI: -2.46; p < 0.0001), but not for the 10 mg group (PDA: -1.19; p = 0.086; PI: -1.08; p = 0.074). In exploratory analyses, atogepant 30 and 60 mg were associated with nominal improvements in MSQ RFP and EF domains, other AIM-D outcomes, and HIT-6 scores at the earliest time point (week 4) and throughout the 12-week treatment period. Results varied for atogepant 10 mg. DISCUSSION: Atogepant 30 and 60 mg produced significant improvements in key patient-reported outcomes including MSQ-RFR scores and both AIM-D domains. Nominal improvements also occurred for other MSQ domains and HIT-6, reinforcing the beneficial effects of atogepant as a new treatment for migraine prevention. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT03777059. Submitted: December 13, 2018; First patient enrolled: December 14, 2018. CLINICALTRIALS: gov/ct2/show/NCT03777059. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that daily atogepant is associated with improvements in health-related quality-of-life measures in patients with 4-14 migraine days per month.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lipton RB, Pozo-Rosich P, Blumenfeld AM, et al. Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial. Neurology. 2022. PMID: 36396451. doi:10.1212/WNL.0000000000201568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。